Compare LARK & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | QTRX |
|---|---|---|
| Founded | 1885 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.5M | 160.0M |
| IPO Year | 2001 | 2017 |
| Metric | LARK | QTRX |
|---|---|---|
| Price | $30.91 | $3.87 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 16.8K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 35.84 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $37,632,000.00 |
| Revenue This Year | N/A | $25.49 |
| Revenue Next Year | N/A | $10.04 |
| P/E Ratio | $37.23 | ★ N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $23.57 | $2.40 |
| 52 Week High | $32.39 | $8.77 |
| Indicator | LARK | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.30 | 51.71 |
| Support Level | $29.91 | $3.77 |
| Resistance Level | $30.80 | $4.57 |
| Average True Range (ATR) | 0.66 | 0.34 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 35.36 | 20.57 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.